SciSparc and Clearmind Medicine Advance Potential Obesity Treatment Through MEAI Research
Aug 7, 2024
Scisparc Investment Portfolios
Clearmind Medicine and SciSparc's Strategic Endeavor in 2023 to Advance Psychedelic Treatments
Jan 5, 2024
SciSparc Announces Intent to Acquire Top Israeli Vehicle Importer
Dec 7, 2023
SciSparc Implements Defensive Shareholder Rights Strategy
Nov 29, 2023
SciSparc Achieves Breakthrough in Weight Loss and Metabolic Disorder Treatment with Psychedelic-Based Therapy
Nov 29, 2023
SciSparc Ltd. Announces Promising Phase IIb Trial Results for SCI-110 in Tourette Syndrome
Nov 14, 2023
SciSparc's SCI-110 Shows Promise in Phase IIb Trial for Tourette Syndrome
Nov 13, 2023
SciSparc Embarks on a Phase IIb Trial of THC-Based Treatment for Tourette Syndrome
Nov 11, 2023